The transjugular route: The key hole to the liver world

Digestive and Liver Disease

Volumn 39, Issue 2, 2007, Pages 105-116

  Senzolo, M ^a,b   Burra, P ^b   Cholongitas, E ^a   Lodato, F ^a   Marelli, L ^a   Manousou, P ^a,c   Patch, D ^a   Sturniolo, G C ^b   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Liver biopsy; Portal hypertension; Portal pressure; Transjugular access

Indexed keywords

DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; HEALTH CARE FACILITY; HEPATIC VEIN; HUMAN; INTERVENTIONAL RADIOLOGY; JUGULAR VEIN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; MEDICAL EDUCATION; NONSURGICAL INVASIVE THERAPY; PATIENT MONITORING; PATIENT SAFETY; PORTAL HYPERTENSION; PORTAL VEIN; PORTOSYSTEMIC ANASTOMOSIS; PRESSURE GRADIENT; RADIOLOGIST; SHORT SURVEY; TREATMENT OUTCOME; VASCULAR ACCESS; VEIN DISEASE; VENOUS PRESSURE;

BIOPSY; HEPATIC VEIN THROMBOSIS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; HYPERTENSION, PORTAL; JUGULAR VEINS; LIVER; LIVER DISEASES; LIVER TRANSPLANTATION; PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RADIOGRAPHY, INTERVENTIONAL; VASCULAR DISEASES; VENOUS PRESSURE; VENOUS THROMBOSIS;

EID: 33846316758     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2006.06.038     Document Type: Short Survey

References (129)

1. Benvegnu L., Gios M., Boccato S., and Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53 (2004) 744-749
2. Rosch J., Hanafee W., Snow H., Barenfus M., and Gray R. Transjugular intrahepatic portacaval shunt. An experimental work. Am J Surg 121 (1971) 588-592
3. Rossle M., and Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol 18 (2004) 99-123
4. Boyer T.D., and Haskal Z.J. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 41 (2005) 386-400
5. Vlachogiannakos J., Patch D., Watkinson A., Tibballs J., and Burroughs A.K. Carbon-dioxide portography: an expanding role?. Lancet 355 (2000) 987-988
6. Sadler D.J., Gordon A.C., Klassen J., Saliken J.C., So C.B., and Gray R.R. Image-guided central venous catheters for apheresis. Bone Marrow Transplant 23 (1999) 179-182
7. Oguzkurt L., Tercan F., Kara G., Torun D., Kizilkilic O., and Yildirim T. US-guided placement of temporary internal jugular vein catheters: immediate technical success and complications in normal and high-risk patients. Eur J Radiol 55 (2005) 125-129
8. Augoustides J.G., Horak J., Ochroch A.E., Vernick W.J., Gambone A.J., Weiner J., et al. A randomized controlled clinical trial of real-time needle-guided ultrasound for internal jugular venous cannulation in a large university anesthesia department. J Cardiothorac Vasc Anesth 19 (2005) 310-315
9. Biernacka J., Nestorowicz A., and Wach M. Intravascular thrombosis as a result of central venous access. Ann Univ Mariae Curie Sklodowska [Med] 57 (2002) 276-284
10. Viallet A., Marleau D., Huet M., Martin F., Farley A., Villeneuve J.P., et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 69 (1975) 1297-1300
11. Garcia-Tsao G., Groszmann R.J., Fisher R.L., Conn H.O., Atterbury C.E., and Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 5 (1985) 419-424
12. Casado M., Bosch J., Garcia-Pagan J.C., Bru C., Banares R., Bandi J.C., et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114 (1998) 1296-1303
13. Gluud C., Henriksen J.H., and Nielsen G. Prognostic indicators in alcoholic cirrhotic men. Hepatology 8 (1988) 222-227
14. Lebrec D., De Fleury P., Rueff B., Nahum H., and Benhamou J.P. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology 79 (1980) 1139-1144
15. Groszmann R.J., Bosch J., Grace N.D., Conn H.O., Garcia-Tsao G., Navasa M., et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 99 (1990) 1401-1407
16. Vorobioff J., Groszmann R.J., Picabea E., Gamen M., Villavicencio R., Bordato J., et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 111 (1996) 701-709
17. Groszmann R.J., Garcia-Tsao G., Bosch J., Grace N.D., Burroughs A.K., Planas R., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005) 2254-2261
18. Abraldes J.G., Tarantino I., Turnes J., Garcia-Pagan J.C., Rodes J., and Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37 (2003) 902-908
19. Boyer T.D. Changing clinical practice with measurements of portal pressure. Hepatology 39 (2004) 283-285
20. Groszmann R.J., and Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 39 (2004) 280-282
21. Thalheimer U., Leandro G., Samonakis D.N., Triantos C.K., Patch D., and Burroughs A.K. Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Dig Liver Dis 37 (2005) 601-608
22. Moitinho E., Escorsell A., Bandi J.C., Salmeron J.M., Garcia-Pagan J.C., Rodes J., et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 117 (1999) 626-631
23. Monescillo A., Martinez-Lagares F., Ruiz-del-Arbol L., Sierra A., Guevara C., Jimenez E., et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 40 (2004) 793-801
24. Aracil C., Lopez-Balanguer J.M., Perez-Rabasco E., Colomo A., Piqueras M., Loras C., et al. Determinants of failure in acute variceal bleeding treated with vasoactive drugs and endoscopic methods. Hepatology 42 Suppl. 1 (2005) 211a [abstract]
25. Abraldes J.G., Aracil C., Catalina M.V., Monescillo A., Banares R., Villanueva C., et al. Value of HVPG predicting 5-day treatment failure in acute variceal bleeding. Comparison with clinical variables. J Hepatol 44 (2006) 47 [abstract]
26. Feu F., Garcia-Pagan J.C., Bosch J., Luca A., Teres J., Escorsell A., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 346 (1995) 1056-1059
27. Villanueva C., Balanzo J., Novella M.T., Soriano G., Sainz S., Torras X., et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 334 (1996) 1624-1629 [abstract]
28. Villanueva C., Minana J., Ortiz J., Gallego A., Soriano G., Torras X., et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 345 (2001) 647-655
29. Thalheimer U., Mela M., Patch D., and Burroughs A.K. Targeting portal pressure measurements: a critical reappraisal. Hepatology 39 (2004) 286-290
30. Bosch J., Abraldes J.G., and Groszmann R. Current management of portal hypertension. J Hepatol 38 Suppl. 1 (2003) S54-S68
31. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43 (2005) 167-176
32. Arroyo V., Bosch J., Gaya-Beltran J., Kravetz D., Estrada L., Rivera F., et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 94 (1981) 198-201
33. Barrett G., Bosch J., Garcia-Tsao G., GRaszmann R.J., Richardson C.R., Navasa M., et al. Hepatic venous pressure gradient as a predictor of survival in patients with cirrhosis. Hepatology 12 (1990) 850
34. Escorsell A., Bordas J.M., Castaneda B., Llach J., Garcia-Pagan J.C., Rodes J., et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 31 (2000) 1061-1067
35. Gluud C., Henriksen J.H., and Nielsen G. Prognostic indicators in alcoholic cirrhotic men. Hepatology 8 (1988) 222-227
36. Merkel C., Bolognesi M., Bellon S., Zuin R., Noventa F., Finucci G., et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 102 (1992) 973-979
37. Ripoll C., Banares R., Rincon D., Catalina M.V., Lo I.O., Salcedo M., et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 42 (2005) 793-801
38. Stanley A.J., Robinson I., Forrest E.H., Jones A.L., and Hayes P.C. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. Q J Med 91 (1998) 19-25
39. Tage-Jensen U., Henriksen J.H., Christensen E., Widding A., Ring-Larsen H., and Christensen N.J. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 6 (1988) 350-358
40. Urbain D., Muls V., Makhoul E., Jeghers O., Thys O., and Ham H.R. Prognostic significance of hepatic venous pressure gradient in medically treated alcoholic cirrhosis: comparison to aminopyrine breath test. Am J Gastroenterol 88 (1993) 856-859
41. Villanueva C., Lopez-Balaguer J.M., Aracil C., Kolle L., Gonzalez B., Minana J., et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 40 (2004) 757-765
42. Vinel J.P., Cassigneul J., Louis A., Levade M., and Pascal J.P. Clinical and prognostic significance of portohepatic gradient in patients with cirrhosis. Surg Gynecol Obstet 155 (1982) 347-352
43. Viola C., Bosch J., Mastai R., Teres J., Navasa M., Kravetz D., et al. Prognostic value of measurements of portal pressure in patients with cirrhosis. J Hepatol 5 Suppl. 1 (1987) S71 [abstract]
44. Zimmerer J., Haubitz I., Mainos D., Hadass H., and Tittor W. Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification. Z Gastroenterol 34 (1996) 421-427
45. Dittrich S., de Mattos A.A., Becker M., Goncaves D.M., and Cheinquer H. Role of hepatic hemodynamic study in the evaluation of patients with cirrhosis. Hepatogastroenterology 50 (2003) 2052-2056
46. Deltenre P., Rufat P., Hillaire S., Elman A., Moreau R., Valla D., et al. Lack of prognostic usefulness of hepatic venous pressures and hemodynamic values in a select group of patients with severe alcoholic cirrhosis. Am J Gastroenterol 97 (2002) 1187-1190
47. Vinel J.P., Cassigneul J., Levade M., Voigt J.J., and Pascal J.P. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology 6 (1986) 116-117
48. Triantos C., Samonakis D., Thalheimer U., Patch D., and Burroughs A. The relationship between liver function and portal pressure: what comes first, the chicken or the egg?. J Hepatol 42 (2005) 146-147
49. Burroughs A.K., Groszmann R., Bosch J., Grace N., Garcia-Tsao G., Patch D., et al. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?. Gut 50 (2002) 425-427
50. Ratti L., Pozzi M., and Bosch J. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Dig Liver Dis 37 (2005) 886-893
51. Nagula S., Jain D., Groszmann R.J., and Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 44 (2006) 111-117
52. Neumann U.P., Berg T., Bahra M., Seehofer D., Langrehr J.M., Neuhaus R., et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 41 (2004) 830-836
53. Berenguer M., Aguilera V., Prieto M., Carrasco D., Rayon M., San Juan F., et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?. Liver Transpl 9 (2003) 1152-1158
54. Samonakis D., Cholongitas E., Triantos C.K., Quaglia A., Senzolo M., Dhillon A.P., et al. Randomised trial of tacrolimus monotherapy vs. tacrolimus/azathioprine/prednisolone after liver transplantation for HCV cirrhosis. J Hepatol 42 S2 (2005) 47 [abstract]
55. Cholongitas E., Senzolo M., Standish R., Marelli L., Quaglia A., Patch D., et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 125 (2006) 710-721
56. Blasco A., Forns X., Carrion J.A., Garcia-Pagan J.C., Gilabert R., Rimola A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43 (2006) 492-499
57. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 (2001) 495-500
58. Lebrec D. Transvenous hepatic puncture-biopsy using the jugular approach. Presse Med 13 (1984) 1605-1606
59. Lebrec D. Various approaches to obtaining liver tissue-choosing the biopsy technique. J Hepatol 25 Suppl 1 (1996) 20-24
60. McAfee J.H., Keeffe E.B., Lee R.G., and Rosch J. Transjugular liver biopsy. Hepatology 15 (1992) 726-732
61. Burroughs A.K., and Dagher L. Liver biopsy. In: Classen M., Tytgat G., and Lightdale C. (Eds). Gastrointestinal endoscopy (2002), Thieme New York, New York 252-259
62. Bull H.J., Gilmore I.T., Bradley R.D., Marigold J.H., and Thompson R.P. Experience with transjugular liver biopsy. Gut 24 (1983) 1057-1060
63. Papatheodoridis G.V., Patch D., Watkinson A., Tibballs J., and Burroughs A.K. Transjugular liver biopsy in the 1990s: a 2-year audit. Aliment Pharmacol Ther 13 (1999) 603-608
64. Cholongitas E., Quaglia A., Samonakis D., Senzolo M., Triantos C., Patch D., et al. Transjugular liver biopsy: how good it is for accurate histological interpretation?. Gut (2006)
65. Rossle M., and Richter G.M.N.G. Performance of an intrahepatic portacaval shunt [PCS] using a catheter tecnique-acase report. Hepatology 8 (1988) 1348A [abstract]
66. Saxon R.R. A new era for transjugular intrahepatic portosystemic shunts?. J Vasc Interv Radiol 15 (2004) 217-219
67. Bureau C., Garcia-Pagan J.C., Otal P., Pomier-Layrargues G., Chabbert V., Cortez C., et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 126 (2004) 469-475
68. Angermayr B., Cejna M., Koenig F., Karnel F., Hackl F., Gangl A., et al. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents. Hepatology 38 (2003) 1043-1050
69. Siegerstetter V., Palmaz J.C., and Rossle M. Migration of self-expandable stents: report of two cases with a tranjugular intrahepatic portosystemic shunt and assessment of stent bending elasticity. Radiology 14 (1999) 137-143
70. Boyer T.D., and Haskal Z.J. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 41 (2005) 386-400
71. Rossle M., Siegerstetter V., Huber M., and Ochs A. The first decade of the transjugular intrahepatic portosystemic shunt (TIPS): state of the art. Liver 18 (1998) 73-89
72. Siegerstetter V., Huber M., Ochs A., Blum H.E., and Rossle M. Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment. Hepatology 29 (1999) 33-38
73. Bureau C., Garcia-Pagan J.C., Otal P., Pomier-Layrargues G., Chabbert V., Cortez C., et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 126 (2004) 469-475
74. Sanyal A.J., Freedman A.M., Luketic V.A., Purdum P.P., Shiffman M.L., Tisnado J., et al. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology 111 (1996) 138-146
75. Jalan R., John T.G., Redhead D.N., Garden O.J., Simpson K.J., Finlayson N.D., et al. A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage. Am J Gastroenterol 90 (1994) 1932-1937
76. Azoulay D., Castaing D., Majno P., Saliba F., Ichai P., Smail A., et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol 35 (2001) 590-597
77. McCormick P.A., Dick R., Panagou E.B., Chin J.K., Greenslade L., McIntyre N., et al. Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding. Br J Surg 81 (1994) 1324-1327
78. Patch D., Nikolopoulou V., McCormick A., Dick R., Armonis A., Wannamethee G., et al. Factors related to early mortality after transjugular intrahepatic portosystemic shunt for failed endoscopic therapy in acute variceal bleeding. J Hepatol 28 (1998) 454-460
79. Chau T.N., Patch D., Chan Y.W., Nagral A., Dick R., and Burroughs A.K. "Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 114 (1998) 981-987
80. Brensing K.A., Raab P., Textor J., Gorich J., Schiedermaier P., Strunk H., et al. Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt: Bonn TIPSS early mortality analysis. Eur J Gastroenterol Hepatol 14 (2002) 723-731
81. Vangeli M., Patch D., Terreni N., Tibballs J., Watkinson A., Davies N., et al. Bleeding ectopic varices-treatment with transjugular intrahepatic porto-systemic shunt (TIPS) and embolisation. J Hepatol 41 (2004) 560-566
82. Burroughs A.K., and Vangeli M. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol 37 (2002) 249-252
83. Senzolo M., Cholongitas E., Tibballs J., Burroughs A., and Patch D. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome. Eur J Gastroenterol Hepatol 18 (2006) 1143-1150
84. Gines P., Uriz J., Calahorra B., Garcia-Tsao G., Kamath P.S., Del Arbol L.R., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123 (2002) 1839-1847
85. Lebrec D., Giuily N., Hadengue A., Vilgrain V., Moreau R., Poynard T., et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. J Hepatol 25 (1996) 135-144
86. Rossle M., Ochs A., Gulberg V., Siegerstetter V., Holl J., Deibert P., et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342 (2000) 1701-1707
87. Salerno F., Merli M., Riggio O., Cazzaniga M., Valeriano V., Pozzi M., et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40 (2004) 629-635
88. Sanyal A.J., Genning C., Reddy K.R., Wong F., Kowdley K.V., Benner K., et al. The North American study for the treatment of refractory ascites. Gastroenterology 124 (2003) 634-641
89. Campbell M.S., Brensinger C.M., Sanyal A.J., Gennings C., Wong F., Kowdley K.V., et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 42 (2005) 635-640
90. Strauss R.M., Martin L.G., Kaufman S.L., and Boyer T.D. Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax. Am J Gastroenterol 89 (1994) 1520-1522
91. Haskal Z.J., and Zuckerman J. Resolution of hepatic hydrothorax after transjugular intrahepatic portosystemic shunt (TIPS) placement. Chest 106 (1994) 1293-1295
92. Nolte W., Figulla H.R., Ringe B., Wiltfang J., Munke H., Hartmann H., et al. Refractory hydrothorax in primary biliary cirrhosis: successful treatment with transjugular intrahepatic portosystemic stent shunt. Dtsch Med Wochenschr 122 (1997) 1275-1280
93. Gordon F.D., Anastopoulos H.T., Crenshaw W., Gilchrist B., McEniff N., Falchuk K.R., et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 25 (1997) 1366-1369
94. Siegerstetter V., Deibert P., Ochs A., Olschewski M., Blum H.E., and Rossle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 13 (2001) 529-534
95. Jeffries M.A., Kazanjian S., Wilson M., Punch J., and Fontana R.J. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg 4 (1998) 416-423
96. Brensing K.A., Textor J., Strunk H., Klehr H.U., Schild H., and Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 349 (1997) 697-698
97. Brensing K.A., Textor J., Perz J., Schiedermaier P., Raab P., Strunk H., et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47 (2000) 288-295
98. Guevara M., Gines P., Bandi J.C., Gilabert R., Sort P., Jimenez W., et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28 (1998) 416-422
99. Testino G., Ferro C., Sumberaz A., Messa P., Morelli N., Guadagni B., et al. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 50 (2003) 1753-1755
100. Wong F., Pantea L., and Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40 (2004) 55-64
101. Senzolo M., Cholongitas E.C., Patch D., and Burroughs A.K. Update on the classification, assessment of prognosis and therapy of Budd-Chiari syndrome. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 182-190
102. Mahmoud A.E., Helmy A.S., Billingham L., and Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 9 (1997) 485-489
103. Eapen C.E., Velissaris D., Heydtmann M., Gunson B., Olliff S., and Elias E. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 55 (2006) 878-884
104. Senzolo M., Cholongitas E., Davies N., Marelli L., Shusang V., Patch D., et al. Transjugular intrahepatic portosystemic shunt (TIPS) is the preferred therapeutic option for Budd Chari syndrome associated with portal vein thrombosis. Am J Gastroenterol 101 (2006) 2163-2164 (letter)
105. Debernardi-Venon W., Bandi J.C., Garcia-Pagan J.C., Moitinho E., Andreu V., Real M., et al. CO(2) wedged hepatic venography in the evaluation of portal hypertension. Gut 46 (2000) 856-860
106. Rossle M., Olschewski M., Siegerstetter V., Berger E., Kurz K., and Grandt D. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 135 (2004) 394-403
107. Hernandez-Guerra M., Turnes J., Rubinstein P., Olliff S., Elias E., Bosch J., et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 40 (2004) 1197-1202
108. Mancuso A., Fung K., Mela M., Tibballs J., Watkinson A., Burroughs A.K., et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 38 (2003) 751-754
109. Perello A., Garcia-Pagan J.C., Gilabert R., Suarez Y., Moitinho E., Cervantes F., et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 35 (2002) 132-139
110. Bureau C., Otal P., Chabbert V., Peron J.M., Rousseau H., and Vinel J.P. Segmental liver ischemia after TIPS procedure using a new PTFE-covered stent. Hepatology 36 (2002) 1554
111. LaBerge J.M., and Kerlan R.K. Liver infarction following TIPS with a PTFE-covered stent: is the covering the cause?. Hepatology 38 (2003) 778-779
112. Baron F., Deprez M., and Beguin Y. The veno-occlusive disease of the liver. Haematologica 82 (1997) 718-725
113. Liatsos C., Mehta A.B., Potter M., and Burroughs A.K. The hepatologist in the haematologists' camp. Br J Haematol 113 (2001) 567-578
114. Mor E., Pappo O., Bar-Nathan N., Shaharabani E., Shapira Z., Tur-Kaspa R., et al. Defibrotide for the treatment of veno-occlusive disease after liver transplantation. Transplantation 72 (2001) 1237-1240
115. Bearman S.I., Anderson G.L., Mori M., Hinds M.S., Shulman H.M., and McDonald G.B. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 11 (1993) 1729-1736
116. Senzolo M., Cholongitas E., Patch D., and Burroughs A.K. TIPS for veno-occlusive disease: Is the contraindication real?. Hepatology 42 (2005) 240-241
117. Settmacher U., Nussler N.C., Glanemann M., Haase R., Heise M., Bechstein W.O., et al. Venous complications after orthotopic liver transplantation. Clin Transplant 14 (2000) 235-241
118. Wang S.L., Sze D.Y., Busque S., Razavi M.K., Kee S.T., Frisoli J.K., et al. Treatment of hepatic venous outflow obstruction after piggyback liver transplantation. Radiology 236 (2005) 352-359
119. Karani J.B., Yu D.F., and Kane P.A. Interventional radiology in liver transplantation. Cardiovasc Intervent Radiol 28 (2005) 271-283
120. Cirera I., Navasa M., Rimola A., Garcia-Pagan J.C., Grande L., Garcia-Valdecasas J.C., et al. Ascites after liver transplantation. Liver Transpl 6 (2000) 157-162
121. Buell J.F., Funaki B., Cronin D.C., Yoshida A., Perlman M.K., Lorenz J., et al. Long-term venous complications after full-size and segmental pediatric liver transplantation. Ann Surg 236 (2002) 658-666
122. Webster G.J., Burroughs A.K., and Riordan S.M. Review article: portal vein thrombosis-new insights into aetiology and management. Aliment Pharmacol Ther 21 (2005) 1-9
123. Cherqui D., Duvoux C., Rahmouni A., Rotman N., Dhumeaux D., Julien M., et al. Orthotopic liver transplantation in the presence of partial or total portal vein thrombosis: problems in diagnosis and management. World J Surg 17 (1993) 669-674
124. Davidson B.R., Gibson M., Dick R., Burroughs A., and Rolles K. Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation 57 (1994) 1174-1177
125. Condat B., Pessione F., Helene D.M., Hillaire S., and Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 32 (2000) 466-470
126. Mancuso A., Fung K., Mela M., Tibballs J., Watkinson A., Burroughs A.K., et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 38 (2003) 751-754
127. Mancuso A., Watkinson A., Tibballs J., Patch D., and Burroughs A.K. Budd-Chiari syndrome with portal, splenic, and superior mesenteric vein thrombosis treated with TIPS: who dares wins. Gut 52 (2003) 438
128. Senzolo M., Tibbals J., Cholongitas E., Triantos C.K., Burroughs A.K., and Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 23 (2006) 767-775
129. Senzolo M, Cholongitas E, Tibballs J, Patch D, Triantos CK, Samonakis D, et al. Relief of biliary obstruction due to portal vein cavernoma using a transjugular intrahepatic portosystemic shunt (TIPS) without the need for long-term stenting. Endoscopy 2006.